Gastrointestinal colonization with a cephalosporinase-producing Bacteroides species preserves colonization resistance against vancomycin-resistant Enterococcus and Clostridium difficile in cephalosporin-treated mice

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4535-4542

  Stiefel, Usha ^a,b   Nerandzic, Michelle M ^a   Pultz, Michael J ^a   Donskeya, Curtis J ^a,b  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTRIAXONE; CEPHALOSPORINASE; RNA 16S; VANCOMYCIN;

ANIMAL; BACTERIAL COUNT; BACTERIUM IDENTIFICATION; BACTEROIDES; DRUG EFFECTS; ENTEROCOCCUS; ENZYMOLOGY; FECES; FEMALE; GASTROINTESTINAL TRACT; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MOUSE; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; RNA GENE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BACTEROIDES; CEFTRIAXONE; CEPHALOSPORINASE; CLOSTRIDIUM DIFFICILE; COLONY COUNT, MICROBIAL; ENTEROCOCCUS; FECES; FEMALE; GASTROINTESTINAL TRACT; GENES, RRNA; MICE; RNA, RIBOSOMAL, 16S; VANCOMYCIN;

EID: 84905401631     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02782-14     Document Type: Article

References (49)

1. Bach PB, Malak SF, Jurcic J, Gelfand SE, Eagan J, Little C, Sepkowitz KA. 2002. Impact of infection by vancomycin-resistant Enterococcus on survival and resource utilization for patients with leukemia. Infect. Control Hosp. Epidemiol. 23:471-474. http://dx.doi.org/10.1086/502089.
2. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, Perl TM, Hammond JM, Hendrix CW. 2002. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med. 28:692-697. http://dx.doi.org/10.1007/s00134-002-1276-8.
3. Montecalvo MA, Jarvis WR, Uman J, Shay DK, Petrullo C, Horowitz HW, Wormser GP. 2001. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting. Infect. Control Hosp. Epidemiol. 22:437-442. http://dx.doi.org/10.1086/ 501931.
4. Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ, Ballow CH. 2000. A nationwide multicenter case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and susceptible enterococcal bacteremia. Diagn. Microbiol. Infect. Dis. 36:145-158. http://dx.doi.org/10.1016/S0732-8893(99)00136-4.
5. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, Bronstein MZ, Trivette SL, Briggs JP, Sexton DJ, Kaye KS. 2003. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36:592-598. http://dx.doi.org/10. 1086/367653.
6. Melzer M, Eykyn SJ, Gransden WR, Chinn S. 2003. Is methicillinresistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin. Infect. Dis. 37:1453-1460. http://dx.doi.org/10.1086/379321.
7. Montecalvo MA, Horowitz H, Gedris C, Carbonaro C, Tenover FC, Issah A, Cook P, Wormser GP. 1994. Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob. Agents Chemother. 38:1363-1367. http://dx.doi.org/10.1128/AAC. 38.6.1363.
8. Wells CL, Juni BA, Cameron SB, Mason KR, Dunn DL, Ferrieri P, Rhame FS. 1995. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin. Infect. Dis. 21:45-50. http://dx.doi.org/10.1093/clinids/21.1. 45.
9. Bhalla A, Pultz NJ, Ray AJ, Hoyen CK, Eckstein EC, Donskey CJ. 2003. Antianaerobic antibiotic therapy promotes overgrowth of antibioticresistant gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect. Control Hosp. Epidemiol. 24:644-649. http://dx.doi.org/10.1086/502267.
10. Ray AJ, Pultz NJ, Bhalla A, Aron DC, Donskey CJ. 2003. Coexistence of vancomycin-resistant enterococci and Staphylococcus aureus in the intestinal tract of hospitalized patients. Clin. Infect. Dis. 37:875-881. http://dx.doi.org/10.1086/377451.
11. Donskey CJ, Ray AJ, Hoyen CK, Fuldauer PD, Aron DC, Salvator A, Bonomo RA. 2003. Colonization and infection with multiple nosocomial pathogens among patients colonized with vancomycin-resistant Enterococcus. Infect. Control Hosp. Epidemiol. 24:242-245. http://dx.doi.org/10.1086/502207.
12. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH. 1972. Origin of infection in acute nonlymphocytic leukemia: significance of hospital acquisition of potential pathogens. Ann. Intern. Med. 77:707-714. http://dx.doi.org/10.7326/0003-4819-77-5-707.
13. Tancrede CH, Andremont AO. 1985. Bacterial translocation and gramnegative bacteremia in patients with hematological malignancies. J. Infect. Dis. 152:99-103. http://dx.doi.org/10.1093/infdis/152.1.99.
14. Wingard JR, Dick J, Charache P, Saral R. 1986. Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrob. Agents Chemother. 30:435. http://dx.doi.org/10.1128/AAC.30.3.435.
15. Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, Ariza J, Gudiol F. 1998. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum betalactamases. Antimicrob. Agents Chemother. 42:53-58.
16. Matar MJ, Tarrand J, Raad I, Rolston KVI. 2006. Colonization and infection with vancomycin-resistant enterococcus among patients with cancer. Am. J. Infect. Control 34:534-536. http://dx.doi.org/10.1016/j.ajic.2006.04.205.
17. Salgado C. 2008. The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients. Am. J. Infect. Control 36:S175.e5-S175.e8. http://dx.doi.org/10.1016/j.ajic.2008.10.010.
18. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr, Kazakova SV, Samboll SP, Johnson S, Gerding DN. 2005. An epidemic, toxin genevariant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441. http://dx.doi.org/10. 1056/NEJMoa051590.
19. Blossom DB, McDonald LC. 2007. The challenges posed by reemerging Clostridium difficile infection. Clin. Infect. Dis. 45:222-227. http://dx.doi.org/10.1086/518874.
20. Vollaard EJ, Clasener HAL. 1994. Colonization resistance. Antimicrob. Agents Chemother. 38:409-414. http://dx.doi.org/10.1128/AAC.38.3.409.
21. Sullivan A, Edlund C, Nord CE. 2001. Effect of antimicrobial agents on the ecological balance of human microbiota. Lancet Infect. Dis. 1:101-114. http://dx.doi.org/10.1016/S1473-3099(01)00066-4.
22. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932. http://dx.doi.org/10.1056/ NEJM200012283432604.
23. Stiefel U, Pultz NJ, Harmoinen J, Koski P, Lindevall K, Helfand MS, Donskey CJ. 2003. Oral administration of β-lactamase preserves colonization resistance of piperacillin-treated mice. J. Infect. Dis. 188:1605-1609. http://dx.doi.org/10.1086/379153.
24. Stiefel U, Harmoinen J, Koski P, Kaariainen S, Wickstrand B, Lindevall K, Pultz NJ, Bonomo RA, Helfand MS, Donskey CJ. 2005. Orally administered recombinant metallo-β-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice. Antimicrob. Agents Chemother. 49:5190-5191. http://dx.doi.org/10.1128/AAC.49.12.5190-5191.2005.
25. Stiefel U, Nerandzic MM, Koski P, Donskey CJ. 2008. Orally administered β-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J. Antimicrob. Chemother. 62:1105-1108. http://dx.doi.org/10.1093/jac/dkn298.
26. Bourgeois S, Tsapis N, Honnas H, Andremont A, Shakweh M, Besnard M, Fattal E. 2008. Colonic delivery of beta-lactamases does not affect amoxicillin pharmacokinetics in rats. J. Pharm. Sci. 97:1853-1863. http://dx.doi.org/10. 1002/jps.21115.
27. Stiefel U, Rao A, Pultz MJ, Jump RL, Aron DC, Donskey CJ. 2006. Suppression of gastric acid production by proton pump inhibitor treatment facilitates colonization of the large intestine by vancomycinresistant Enterococcus spp. and Klebsiella pneumoniae in clindamycintreated mice. Antimicrob. Agents Chemother. 50:3905-3907. http://dx.doi.org/10.1128/AAC.00522- 06.
28. Stiefel U, Pultz NJ, Helfand MJ, Donskey CJ. 2004. Increased susceptibility to establishment of vancomycin-resistant Enterococcus intestinal colonization persists after completion of antianaerobic antibiotic treatment in mice. Infection Control Hosp. Epidemiol. 25:373-379. http://dx.doi.org/10.1086/ 502408.
29. Pultz NJ, Stiefel U, Ghannoum M, Helfand MJ, Donskey CJ. 2005. Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice. Antimicrob. Agents Chemother. 49:438-440. http://dx.doi.org/10.1128/AAC.49.1.438-440.2005.
30. Pultz NJ, Stiefel U, Subramanyan S, Helfand MS, Donskey CJ. 2005. Mechanisms by which anaerobic microbiota inhibit the establishment in mice of intestinal colonization by vancomycin-resistant Enterococcus. J. Infect. Dis. 191:949-956. http://dx.doi.org/10.1086/428090.
31. Pultz NJ, Stiefel U, Donskey CJ. 2005. Effects of daptomycin, linezolid and vancomycin on establishment of intestinal colonization with vancomycinresistant enterococci and extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae in mice. Antimicrob. Agents Chemother. 49:3513-3516. http://dx.doi.org/10.1128/AAC.49.8.3513-3516.2005.
32. Stiefel U, Pultz NJ, Donskey CJ. 2007. Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice. Antimicrob. Agents Chemother. 51:372-375. http://dx.doi.org/10.1128/AAC.00355-06.
33. Pultz MJ, Nerandzic MM, Stiefel U, Donskey CJ. 2008. Emergence and acquisition of fluoroquinolone-resistant gram-negative bacilli in the intestinal tracts of mice treated with fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother. 52:3457-3460. http://dx.doi.org/10.1128/AAC.00117-08.
34. Borriello SP, Barclay FE, Welch AR. 1988. Evaluation of the predictive capability of an in-vitro model of colonization resistance to Clostridium difficile infection. Microb. Ecol. Health Dis. 1:61-64. http://dx.doi.org/10. 3109/08910608809140181.
35. Pultz NJ, Donskey CJ. 2005. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob. Agents Chemother. 49:3529-3532. http://dx.doi.org/10.1128/AAC.49.8. 3529-3532.2005.
36. Adams DA, Riggs MM, Donskey CJ. 2007. Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the cecal contents of mice. Antimicrob. Agents Chemother. 51:2674-2678. http://dx.doi.org/10.1128/AAC.01582-06.
37. O'Callaghan CH, Morris A, Kirby SM. 1972. Novel method for detection of β-lactamases by using a chromogenic cephalosporin substrate. Antimicrob. Agents Chemother. 1:283-288. http://dx.doi.org/10.1128/AAC.1.4.283.
38. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. 2003. Comparison of community- and health care-associated methicillin-resistant S. aureus infection. JAMA 290:2976-2984. http://dx.doi.org/10.1001/jama.290.22. 2976.
39. Tschudin-Sutter S, Tamma PD, Naegeli N, Speck KA, Perl T. 2013. Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance. Clin. Infect. Dis. 57:1665-1672. http://dx.doi.org/10.1093/cid/cit581.
40. Dellit TH, Owens RC, McGowan JE, Jr, Gerding DN, Weinstein RA, Burke JP, Huskins WC, Paterson DL, Fishman NO, Carpenter CF, Brennan PJ, Billeter M, Hooton TM, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America. 2007. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44:159-177. http://dx.doi.org/10.1086/510393.
41. Yokoe DS, Mermel LA, Anderson DJ, Arias KM, Burstin H, Calfee DP, Coffin SE, Dubberke ER, Fraser V, Gerding DN, Griffin FA, Gross P, Kaye KS, Klompas M, Lo E, Marschall J, Nicolle L, Peguew DA, Perl TM, Podgorny K, Saint S, Salgado CD, Weinstein RA, Wise R, Classen D. 2008. Executive summary: a compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect. Control Hosp. Epidemiol. 29(S1):S12-S21. http://dx.doi.org/10.1086/ 591060.
42. Derde LP, Cooper BS, Goossens H, Malhotra-Kumar S, Willems RJ, Gniadkowski M. 2014. Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect. Dis. 14:31-39. http://dx.doi.org/10.1016/S1473-3099(13)70295-0.
43. Sitzlar B, Deshpande A, Fertelli D, Kundrapu S, Sethi AK, Donskey CJ. 2013. An environmental disinfection odyssey: evaluation of sequential interventions to improve disinfection of Clostridium difficile isolation rooms. Infect. Control Hosp. Epidemiol. 34:459-465. http://dx.doi.org/10.1086/670217.
44. Léonard F, Andremont A, Leclerq B, Labia R, Tancrède C. 1989. Use of beta-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization. J. Infect. Dis. 160:274-280. http://dx.doi.org/10.1093/infdis/160.2.274.
45. Olsson B, Dornbusch K, Nord CE. 1977. Susceptibility to β-lactam antibiotics and production of beta-lactamase in Bacteroides fragilis. Med. Microbiol. Immunol. 163:183-194. http://dx.doi.org/10.1007/BF02126677.
46. Nord CE. 1986. Mechanisms of β-lactam resistance in anaerobic bacteria. Rev. Infect. Dis. 8(Suppl 5):S543-S548. http://dx.doi.org/10.1093/ clinids/8.Supplement-5.S543.
47. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Rihs J, Gorbach SL. 2007. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Antimicrob. Agents Chemother. 51:1649-1655. http://dx.doi.org/10.1128/AAC.01435-06.
48. Wexler H. 2007. Bacteroides: the good, the bad, and the nitty-gritty. Clin. Microbiol. Rev. 20:593-621. http://dx.doi.org/10.1128/CMR.00008-07.
49. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368:407-415. http://dx.doi.org/10.1056/ NEJMoa1205037.